© 2021 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2021 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
July 29, 2021
How is “disease” defined? A popular criticism of psychiatry gets debunked.
July 23, 2021
Although the new drug aducanumab has grabbed all the headlines, the future of Alzheimer treatment may be just as much about public health campaigns as it is about psychopharmacology. In this episode of Psych Pearls, we find out why.
July 14, 2021
Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?
July 01, 2021
Travelling the middle road between skepticism and scientism in psychiatric research and treatment.
June 18, 2021
The emergence of epigenetic models has generated a surge of optimism, opening new possibilities for psychiatric intervention.
A brain-based perspective could explain how and why psychotherapy leads to enduring change.
June 16, 2021
The FDA approval of aducanumab has given hope to millions of patients with Alzheimer disease—but will it live up to the hype?
June 10, 2021
A driving force.
June 09, 2021
A Psychiatric Times point/counterpoint feature on electroconvulsive therapy elicited strong responses.
This is a rare opportunity for researchers and entrepreneurs from a variety of fields to conduct experiments in space.